These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 30040929)
1. The protective and anti-inflammatory effects of a modified glucagon-like peptide-2 dimer in inflammatory bowel disease. Gu J; Liu J; Huang T; Zhang W; Jia B; Mu N; Zhang K; Hao Q; Li W; Liu W; Zhang W; Zhang Y; Xue X; Zhang C; Li M Biochem Pharmacol; 2018 Sep; 155():425-433. PubMed ID: 30040929 [TBL] [Abstract][Full Text] [Related]
2. New Peptide Inhibitor of Dipeptidyl Peptidase IV, EMDB-1 Extends the Half-Life of GLP-2 and Attenuates Colitis in Mice after Topical Administration. Salaga M; Mokrowiecka A; Zielinska M; Malecka-Panas E; Kordek R; Kamysz E; Fichna J J Pharmacol Exp Ther; 2017 Oct; 363(1):92-103. PubMed ID: 28724693 [TBL] [Abstract][Full Text] [Related]
3. A DPP-IV-resistant glucagon-like peptide-2 dimer with enhanced activity against radiation-induced intestinal injury. Gu J; Liu S; Mu N; Huang T; Zhang W; Zhao H; Shu Z; Zhang C; Hao Q; Li W; Xue X; Zhang W; Zhang Y J Control Release; 2017 Aug; 260():32-45. PubMed ID: 28522195 [TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase 4 inhibitor sitagliptin protected against dextran sulfate sodium-induced experimental colitis by potentiating the action of GLP-2. Ning MM; Yang WJ; Guan WB; Gu YP; Feng Y; Leng Y Acta Pharmacol Sin; 2020 Nov; 41(11):1446-1456. PubMed ID: 32398684 [TBL] [Abstract][Full Text] [Related]
5. G protein-coupled receptor 40 activation ameliorates dextran sulfate sodium-induced colitis in mice via the upregulation of glucagon-likepeptide-2. Kato S; Utsumi D; Matsumoto K J Pharmacol Sci; 2019 Jun; 140(2):144-152. PubMed ID: 31242961 [TBL] [Abstract][Full Text] [Related]
6. Deficiency of the intestinal growth factor, glucagon-like peptide 2, in the colon of SCID mice with inflammatory bowel disease induced by transplantation of CD4+ T cells. Schmidt PT; Hartmann B; Bregenholt S; Hoist JJ; Claesson MH Scand J Gastroenterol; 2000 May; 35(5):522-7. PubMed ID: 10868456 [TBL] [Abstract][Full Text] [Related]
7. Purified PEGylated porcine glucagon-like peptide-2 reduces the severity of colonic injury in a murine model of experimental colitis. Qi KK; Wu J; Wan J; Men XM; Xu ZW Peptides; 2014 Feb; 52():11-8. PubMed ID: 24274971 [TBL] [Abstract][Full Text] [Related]
8. Glugacon-like peptide-2: broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration. El-Jamal N; Erdual E; Neunlist M; Koriche D; Dubuquoy C; Maggiotto F; Chevalier J; Berrebi D; Dubuquoy L; Boulanger E; Cortot A; Desreumaux P Am J Physiol Gastrointest Liver Physiol; 2014 Aug; 307(3):G274-85. PubMed ID: 24875097 [TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase expression during experimental colitis in mice. Yazbeck R; Sulda ML; Howarth GS; Bleich A; Raber K; von Hörsten S; Holst JJ; Abbott CA Inflamm Bowel Dis; 2010 Aug; 16(8):1340-51. PubMed ID: 20186930 [TBL] [Abstract][Full Text] [Related]
10. Vasoactive Intestinal Peptide Nanomedicine for the Management of Inflammatory Bowel Disease. Jayawardena D; Anbazhagan AN; Guzman G; Dudeja PK; Onyuksel H Mol Pharm; 2017 Nov; 14(11):3698-3708. PubMed ID: 28991483 [TBL] [Abstract][Full Text] [Related]
14. Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward? Yazbeck R; Howarth GS; Abbott CA Cytokine Growth Factor Rev; 2009 Apr; 20(2):175-84. PubMed ID: 19324585 [TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis. L'Heureux MC; Brubaker PL J Pharmacol Exp Ther; 2003 Jul; 306(1):347-54. PubMed ID: 12815012 [TBL] [Abstract][Full Text] [Related]
16. New frontiers in the biology of GLP-2. Lovshin J; Drucker DJ Regul Pept; 2000 Jun; 90(1-3):27-32. PubMed ID: 10828489 [TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Hartmann B; Thulesen J; Kissow H; Thulesen S; Orskov C; Ropke C; Poulsen SS; Holst JJ Endocrinology; 2000 Nov; 141(11):4013-20. PubMed ID: 11089531 [TBL] [Abstract][Full Text] [Related]
18. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. Alavi K; Schwartz MZ; Palazzo JP; Prasad R J Pediatr Surg; 2000 Jun; 35(6):847-51. PubMed ID: 10873024 [TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-2-loaded microspheres as treatment for ulcerative colitis in the murine model. Wu J; Qi K; Xu Z; Wan J J Microencapsul; 2015; 32(6):598-607. PubMed ID: 26218715 [TBL] [Abstract][Full Text] [Related]
20. Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats. Washizawa N; Gu LH; Gu L; Openo KP; Jones DP; Ziegler TR JPEN J Parenter Enteral Nutr; 2004; 28(6):399-409. PubMed ID: 15568286 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]